CD38 and Miyoshi myopathy: Indeed, the anti-CD38 mAbs inhibit immunosuppression exerted by regulatory T cells in MM [44–46] in addition to inducing myeloma cell death via lysosomal-associated and apoptotic pathways, which can be further enhanced by immunomodulatory drugs (IMiDs) [47].